Merck Sharp + Dohme Corp.

Schering Corporation

Merck Gmbh

Weidong Pan

Stephane L Bogen

Latha G Nair

Haifeng Tang

Matthew Ernst Voss

Jing Su

Yaolin Wang

Mihir Mandal

Shu-Wei Yang

Ronald J Doll

F George Njoroge

Gerald Wayne Shipps, Jr

Fa-Xiang Ding

Manami Shizuka

Craig R Gibeau

Jianping Pan

Yuan Tian

Yao Ma

Brian Robert Lahue

Viyyoor Moopil Girijavallabhan

Tesfaye Biftu

William K Hagmann

Timothy J Guzi

Anil K Saksena

Alexander Pasternak

Frank W Bennett

Qun Dang

Xianhai Huang

Ashok Arasappan

Srikanth Venkatraman

Jinlong Jiang

Kevin X Chen

Guoqing Li

Ian W Davies

Li Xiao

Vinay M Girijavallabhan

Shuzhi Dong

Wanying Sun

Christina B Madsen-Duggan

John P Caldwell

Ginny Dai Ho

Weiguo Liu

Marc A Labroli

Haiqun Tang

Sookhee Nicole Ha

Mousumi Sannigrahi

Min K Park

Dexi Yang

Yuan Liu

Yi Zang

Christine Yang

Zheng Tan

Sandra J Koseoglu

Sang Ho Lee

Terry Roemer

Christopher Michael Tan

Hao Wang

Reynalda DeJesus

Mark A McCoy

Margarita Kirova-Snover

Malcolm MacCoss

Christopher J Dinsmore

Corey Strickland

Malcolm Maccoss

Michelle R Machacek

B Wesley Trotter

Zhuyan Guo

Helen Y Chen

Xin Gu

Christopher Francis Thompson

Anthony K Ogawa

Yan Guo

Michael Hale Reutershan

Bheemashankar A Kulkarni

Linda Brockunier

Matthew Christopher

Clare London

Christopher W Plummer

Rumin Zhang

Binyuan Sun

Zhiqiang Zhao

Jacqueline D Hicks

Yuhua Huang

Francesc Xavier Fradera Llinas

Liping Yang

Michelle Martinez

Katherine Young

Gerald W Shipps

Hongwu Wang

Chaomin Li

Rudrajit Mal

Hong Dong Chu

Dipshikha Biswas

Matthew Lombardo

Amin Nomeir

Carolyn Michele Cammarano

David N Hunter

Dietrich P Steinhuebel

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a &#x3b2;-lactam antibiotic.

Benzimidazoles and indoles as taro inhibitors

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. 

Chromane monobactam compounds for the treatment of bacterial infections

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a &#x3b2;-lactam antibiotic. 

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Metallo-beta-lactamase inhibitors

The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7,8 substituted purines as HDM2 inhibitors

2'-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (1), wherein A is Nor NHand X, Y, R, R, R, R, Rand Rare as defined herein. Compositions comprising at least one 2&#x2032;-disubstituted nucleoside derivative, and methods of using the 2&#x2032;-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed. 

2'-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

Compounds of Formula (I) are disclosed, wherein R, R, R, R, R, and Rare defined herein. The compounds encompassed by Formula (I) include compounds which are HCV NS5B inhibitors and other compounds which can be metabolized in vivo to HCV NS5B inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. 

Substituted piperidines as HDM2 inhibitors

The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Substituted piperidines that increase p53 activity and the uses thereof

In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

Substituted piperidines that increase P53 activity and the uses thereof

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease

Inhibitors of hepatitis C virus NS3 protease

Growing community of inventors

Hillsborough, NJ, United States of America

Weidong Pan